Minerva Neurosciences
Develops roluperidone for negative symptoms of schizophrenia through a confirmatory Phase 3 trial.
Something off on this page? Send us feedback.
Profile
Develops roluperidone, a clinical-stage candidate for negative symptoms of schizophrenia. The business is centered on a global confirmatory Phase 3 trial after the FDA declined its prior NDA.
Develops roluperidone for negative symptoms in people diagnosed with schizophrenia. The clinical-stage program is the operating focus, rather than a portfolio of approved medicines.
A global confirmatory Phase 3 study began after the FDA issued a Complete Response Letter for the previous NDA. Any future resubmission depends on that additional study and its safety and efficacy record.
The lean development model relies on a small internal team, consultants, and outside companies for product-development functions. The program's regulatory path remains shaped by the FDA's requirement for an additional adequate, well-controlled study.
Company facts
Key statistics
Year to date +23.0% · Average volume (30d) 221.8K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Jefferies | Upgrade | Mixed | Buy | $5 | $10 |
| Dec 1, 2025 | Jefferies | Target | $5 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026Q2 FY26 | −$0.19 | −$0.14 | +27.6% | — | — | — | −3.83% |
| May 5, 2026Q1 FY26 | −$0.13 | −$0.17 | −30.8% | — | — | — | −0.32% |
| Mar 11, 2026Q4 FY25 | −$0.11 | −$0.64 | −481.8% | — | — | — | +5.34% |
| Nov 5, 2025Q3 FY25 | −$0.35 | −$0.36 | −2.9% | — | — | — | −4.71% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | |
| Operating income | −$3.9M | −$3.4M | −$2.8M | −$5.0M | −$16.7M | −$10.6M | |
| Net income | −$3.8M | −$3.3M | −$2.7M | −$283.7M | −$125.4M | $17.5M | |
| Diluted EPS | −$0.50 | −$0.43 | −$0.36 | −$25.51 | −$2.86 | −$0.14 | |
| Gross margin | — | — | — | — | — | — | |
| Operating margin | — | — | — | — | — | — |
Fiscal years (4-quarter sums)FY21 $0 · FY22 $0 · FY23 $0 · FY24 $0 · FY25 $0
Balance sheet, Jun 30, 2026Cash & short-term investments $75.3M · Total debt $0 · Total assets $95.1M · Shareholders' equity −$201.6M
Dividends
No dividends on record.
Ownership
Shares outstanding 46.59M · Float 37.99M · 81.5% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 8.59M | 9.99% | 13G | Dec 31, 2025 |
| Federated Hermes, Inc. | 5.11M | 10.98% | 13F | May 11, 2026 |
| Coastlands Capital LP | 4.56M | 9.99% | 13G | Feb 20, 2026 |
| Balyasny Asset Management L.P. | 4.32M | 9.99% | 13G | May 15, 2026 |
| Vivo Capital, LLC | 4.32M | 9.28% | 13F | May 20, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
View detailsPeers
- Reviva Pharmaceuticals
Late-stage brilaroxazine program also pursuing schizophrenia
- Bristol-Myers Squibb
New oral schizophrenia therapy with a muscarinic mechanism
- Johnson & Johnson
Once-daily oral CAPLYTA for adult schizophrenia
- AbbVie
Oral atypical antipsychotic for schizophrenia
- Alkermes
Olanzapine/samidorphan treatment for adult schizophrenia
- Teva (ADR)
Long-acting subcutaneous risperidone for adult schizophrenia
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Minerva Neurosciences | $4.89 | +1.45% | $225.5M | — | — | — | — |
| Reviva Pharmaceuticals | $0.5150 | −0.68% | $6.6M | — | — | — | — |
| Bristol-Myers Squibb | $66.60 | +0.05% | $136.00B | 14.7 | 10.5 | 2.8 | +5.7% |
| Johnson & Johnson | $268.40 | +0.13% | $645.95B | 31.1 | 22.4 | 6.6 | +6.6% |
| AbbVie | $255.80 | +0.13% | $451.38B | 72.0 | 16.8 | 7.0 | +10.2% |
| Alkermes | $47.25 | −0.34% | $7.95B | 123.8 | — | 4.8 | +27.0% |
| Teva (ADR) | $36.30 | −0.36% | $42.44B | 60.7 | 12.9 | 2.5 | −0.8% |
| Median | 60.7 | 14.9 | 4.8 | +6.6% |